A multi-center translational study will be conducted in order to evaluate the ability of a bedside optical technology to monitor neoadjuvant chemotherapy response in breast cancer patients with locally-advanced disease. The technology, Diffuse Optical Spectroscopic Imaging (DOSI), will be combined with MRI and biomarkers that provide anatomic and molecular correlates, respectively. The proposed studies build on the infrastructure established by the NCI Network for Translational Research in Optical Imaging (NTROI), which has allowed us to validate and standardize DOSI-MRI co-registration methods, data analysis, histopathology, and protocol design. Five clinical sites with identical DOSI instruments and MRI protocols will participate: University of California, Irvine, University of California, San Francisco, University of Pennsylvania, Dartmouth, and Harvard/MGH. A 6th site, Siemens Corporate Research, will provide data and informatics support using specially developed software. The proposed NTR will be integrated into 2 well-established NCI programs supported by ACRIN and I-SPY in order to leverage DOSI with standard MRI and tissue biomarker protocols. Developmental studies will explore blood biomarkers, as well as social and economic factors affecting the acceptance of DOSI for breast cancer chemotherapy management. The resulting NTR-ACRIN-ISPY partnership will facilitate the first multi-center, multi-modality study designed to validate the role of optics in monitoring and predicting response to cancer chemotherapies. Our long-term goal is to provide oncologists with quantitative, non-invasive, standardized optical endpoints that can be used to rapidly optimize therapy for individual breast cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA136400-03
Application #
8340233
Study Section
Special Emphasis Panel (ZCA1-SRRB-9 (O1))
Project Start
2011-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
3
Fiscal Year
2011
Total Cost
$378,537
Indirect Cost
Name
University of California Irvine
Department
Type
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Cochran, J M; Chung, S H; Leproux, A et al. (2017) Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy. Phys Med Biol 62:4637-4653
Tromberg, Bruce J; Zhang, Zheng; Leproux, Anaïs et al. (2016) Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res 76:5933-5944
Leproux, Anaïs; Kim, You Me; Min, Jun Won et al. (2016) Differential diagnosis of breast masses in South Korean premenopausal women using diffuse optical spectroscopic imaging. J Biomed Opt 21:74001
O'Sullivan, Thomas D; Leproux, Anaïs; Chen, Jeon-Hor et al. (2013) Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy. Breast Cancer Res 15:R14
Roblyer, Darren; O'Sullivan, Thomas D; Warren, Robert V et al. (2013) Feasibility of Direct Digital Sampling for Diffuse Optical Frequency Domain Spectroscopy in Tissue. Meas Sci Technol 24:045501
Leproux, Anaïs; Durkin, Amanda; Compton, Montana et al. (2013) Assessing tumor contrast in radiographically dense breast tissue using Diffuse Optical Spectroscopic Imaging (DOSI). Breast Cancer Res 15:R89
O'Sullivan, Thomas D; Cerussi, Albert E; Cuccia, David J et al. (2012) Diffuse optical imaging using spatially and temporally modulated light. J Biomed Opt 17:071311
Cerussi, Albert E; Warren, Robert; Hill, Brian et al. (2012) Tissue phantoms in multicenter clinical trials for diffuse optical technologies. Biomed Opt Express 3:966-71
Chung, So Hyun; Yu, Hon; Su, Min-Ying et al. (2012) Molecular imaging of water binding state and diffusion in breast cancer using diffuse optical spectroscopy and diffusion weighted MRI. J Biomed Opt 17:071304
Ueda, Shigeto; Roblyer, Darren; Cerussi, Albert et al. (2012) Baseline tumor oxygen saturation correlates with a pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy. Cancer Res 72:4318-28

Showing the most recent 10 out of 21 publications